Authors: J. Štolfa Authors‘ workplace: Revmatologický ústav, Praha Published in: Čes. Revmatol., , 2004, No. 4, p. 175-183. Category:
Psoriatic arthritis is a potentially serious disorder leading to a significant disability in 20–30 % ofpatients. Pharmacological treatment is limited to non-steroidal anti-inflammatory drugs, sulfasalazine,methotrexate and cyclosporine A. In contrast to rheumatoid arthritis, there has not been anybiological agent registered in the Czech Republic yet. The registration is expected in 2005. Indicationcriteria and methods of monitoring of biological treatment before its assumed registration in2005 are summarized in the present paper.
Key words: psoriatic arthritis, biologic treatment, standard methods
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
